Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Acrivon Therapeutics, Inc. (ACRV) Stock Price & Analysis
108 Followers
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $14.30
Previous Close$8.36
Volume38.55K
Average Volume (3M)801.43K
Market Cap
$258.12M
Enterprise Value$135.30M
Total Cash (Recent Filing)$127.46M
Total Debt (Recent Filing)$4.64M
Price to Earnings (P/E)-2.9
Beta0.80
Next Earnings
Aug 09, 2024EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding30,871,951
10 Day Avg. Volume175,203
30 Day Avg. Volume801,427
Standard Deviation0.27
R-Squared0.04
Alpha-0.00035
Financial Highlights & Ratios
Price to Book (P/B)2.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.01K
Enterprise Value/Gross Profit1.01K
Enterprise Value/Ebitda-2.81
Forecast
1Y Price Target
$23.00Price Target Upside165.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Acrivon Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentInitial data from ACR-368 establishes proof of concept for enriching responders, generating a 50% objective response rate in ovarian and endometrial cancer patients.
Financial OutlookAcrivon Therapeutics, Inc. reported initial prospective data that supports its oncology platform and has successfully raised $130M from fundamental healthcare investors.
Regulatory MilestoneExpedited IND submission for ACR-2316 is on track, with promising preclinical data suggesting superior efficacy compared to existing inhibitors.
Bears Say
Clinical TrialsBladder cancer patient enrollment is lagging, potentially due to recent approval of competitive treatments in the market, indicating a loss of competitive edge for ACRV.
Drug EfficacyOncoSig negative patients potentially needs a different combination regimen or an increased dose to induce deeper responses, suggesting the current treatment may not be sufficiently effective.
Financial PerformanceACRV reported a significant net loss which may reflect challenges in the company's financial stability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $14.30 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Aug 09, 2024 which is in 85 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on May 14, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.84 by $0.11.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -$0.6.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 30,875,456 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.84. Following the earnings report the stock price went down -1.415%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 24M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (165.90% Upside)
$23.00 (165.90% Upside)
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 6.4%
Last 30 Days ▲ 19.6%
Last 30 Days ▲ 19.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.84%
12-Months-Change
Fundamentals
Return on Equity
-47.77%
Trailing 12-Months
Asset Growth
-29.19%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$23.00
▲(165.90% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
+19.10%
reiterated a buy rating 2 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.10% per trade.
---